In our Ask the Expert Series, we interview leaders from our partner organizations who are helping lead their brands to new heights in AdTech. Today’s interview is with Rachel Herbstman, VP of Data Innovation, and Anastasia Dukes-Asuen, Senior Director of Advanced TV Data & Insights at Ampersand.
Could you introduce us to Ampersand and discuss your approach to TV advertising?
Ampersand, a joint venture between Comcast, Charter, and Cox, is a media sales organization that offers a unified footprint, unlocking unparalleled scale and unique data/insights for local and national advertisers. Ampersand gives advertisers true audience first planning, scale in execution, and advanced measurement of their TV investments, representing 117 million multiscreen households and over 75% of addressable households in the U.S. (64 million households). We help clients reach their unique target audience and deliver their stories – anytime, anywhere, and on whatever device.
How does adding streaming to a linear campaign, or vice versa, enhance overall campaign performance for marketers?
Herbstman: Marketers have recognized that multiscreen media strategies are the strongest as viewership continues to fragment. Unique audiences exist in traditional TV and streaming, and failure to include either media channel will reduce the total reach opportunity. These channels have proven to validate unduplicated audiences.
In our local business, adding streaming to a historically traditional linear-only media strategy increased campaign reach by 33%. Conversely, adding linear TV to a historically streaming-only media strategy increased reach by 209%. These metrics are validated by matching media exposures to an authenticated households subscriber ID and represent mass opportunities to reach new audiences with a multiscreen media strategy.
When considering reallocating media investments, how does Ampersand help clients determine the most effective channels for specific campaigns?
Herbstman: For a brand that historically invested in traditional TV, either national or local broadcast, we can provide insights to analyze the performance of any media campaign. The insights can include high-level metrics like reach and frequency and more granular metrics like unique reach per network. By seeing both the high-level results and more detailed granularity, we can provide optimization recommendations for funding other activation opportunities.
Our database of past campaigns consistently demonstrates that gaining new eyeballs with a national TV campaign usually plateaus after a few weeks. In other words, if most of your intended audience is reached after about three or four weeks of national television, reaching any new viewers can be exponentially more expensive.
We’ve built an Addressable Simulator tool for national advertisers that shows the potential impact of shifting a portion of the national media weight, specifically from the latter part of a flight, into addressable TV. Using our licensed Experian data set, we can measure any standard age/gender target or any advanced target to understand the complementary impact that addressable audience has on national media. This tool has dynamic inputs of CPMs and incidence rates, flight lengths, and budgets to simulate different scenarios and give marketers some intelligence on what holistic reach against that Experian segment they could expect with one given budget using brand-safe, traditional, and streaming inventory with an addressable activation.
Additionally, we’ve developed an interactive eCPM calculator that helps national advertisers assess the cost efficiency of adding addressable TV to their traditional campaigns. By dynamically inputting CPMs, marketers can evaluate tradeoffs between media types for upcoming campaigns.
Are there audience demographics that benefit from these combined media strategies, and what indicators or data points guide your recommendations to add cable to a local broadcast campaign versus other reallocations?
Herbstman: By including cable or streaming in a local effort, a client can use a data-driven approach to find more intended viewers in other premium content. Utilizing the vast library of Experian audience segments paired with our robust sample of 64 million data-enabled homes enables Ampersand to provide insights into the most valuable networks and dayparts that the intended viewer will likely watch on either platform.
With identity and viewing insights at scale, we can understand how consumers watch TV, even for inventory we have yet to sell. Our goal is to help marketers understand what’s happening as a result of their investments at a holistic level.
We can analyze a campaign running across hundreds of designated market areas to quickly and simply understand the holistic delivery of their broadcast and cable weight by pulling back set-top-box exposures on broadcast and Ampersand-purchased cable on our measurable footprint. Then, we can determine the share of measurable reach that each portion’s media weight contributes to.
We recommend optimizing towards a more balanced approach, where the reach levels for broadcast and cable mirror each other, creating a more effective market media mix.
Once we confirm cable’s potential in a market, we analyze network and daypart metrics to adjust key areas to optimize the campaign. We invite marketers to use these insights to measure their local or national TV campaign performance and garner unique perspectives to re-balance investments to drive reach and optimal frequencies.
Are there common missteps to avoid?
Dukes-Asuen: Ampersand’s decades of experience with media and data insights have allowed us to create an extensive database complete with targeting and measurement benchmarks. We use this database to curate best practices for brands and help set them up for success, keeping their goals and objectives for reach and frequency in mind.
Some clients spread their investment levels too thin, whether through short flight windows, low weekly frequencies, or targeting overly niche audiences that don’t fully support KPI goals.
One way to avoid these missteps is to set up a test-and-learn plan to validate a hypothesis and refine media strategies, ensuring campaigns are structured to garner meaningful insights. Ampersand can help ensure the test itself is constructed and supported to yield statistically relevant results, and the learnings can then be applied to the next campaign.
How does Experian’s data enhance your campaigns at Ampersand?
Dukes-Asuen: Within our Experian license, we can map the Experian Consumer View databases against our multichannel video programming distributors subscriber base in a privacy-compliant way to plan and activate them seamlessly. Experian has a rich set of audience targets and segmentation that we utilize to identify households that can be used for audience-based media execution with Ampersand. By defining the right audience—whether consumers are likely to purchase a product, exhibit certain behaviors, or demonstrate specific values—we enhance campaign performance and improve media spending efficiency for our advertisers.
Additionally, how do you believe AI and other new technologies will impact your media buying approaches in the future, and how might these innovations improve campaign effectiveness and provide value to your clients?
Herbstman: We have a strong use case on the measurement and analytics end. Using AI, we can aggregate a massive amount of historical data—viewership and exposure data. AI helps us understand overarching market trends and media performance to analyze campaign results and inform future campaign optimizations. The value of AI is in its role as an additional technology layer, enriching our insights portfolio and providing faster intelligence that enhances campaign effectiveness and delivers greater value to our clients.
Can you share an example of how precise audience targeting and segmentation, powered by Experian, have led to significantly better media spend reallocations and campaign performance for marketers?
One great example is how a national cruise brand dramatically improved its media spend and campaign performance by utilizing precise audience targeting and segmentation through Experian. By combining Ampersand’s addressable TV with Experian’s data-driven insights, they achieved a 14% incremental reach, a 3.1x higher frequency, and a 24% lower effective CPM. This strategic approach allowed them to reallocate their media spending more effectively, ensuring every impression reached their custom target audience.
Thanks for the interview.
For those interested in learning more about Ampersand, reach out for a personalized consultation.
Latest posts
Privacy-forward pharma media supports more informed healthcare journeys Effective pharma marketing depends on reaching patients, caregivers, and healthcare professionals (HCPs) with useful information in appropriate, privacy-forward ways. The goal is to make relevant education easier to find, support more informed conversations, and help brands understand how media contributes across the health journey. In this Ask the Expert session, Natalie Mancuso, SVP, Data Partnerships at DeepIntent, joins Sheila Wirick, who leads the health team at Experian, to discuss how to craft patient and HCP campaigns, privacy-safe activation workflows, connected TV (CTV), and measurement approaches built for pharma. Why should your media plan start with understanding the patient and provider The patient-and-provider journey should inform your media plan, as treatment decisions in pharma are increasingly informed, personal, and patient-driven. With more health information available than ever, patients are playing a more active role in understanding their options and participating in treatment conversations. As other industries become more customer-centric, pharma media planning needs to become more patient-centric. “We’ve got patients who are more informed, more involved in their treatment decisions than ever. The accessibility of data and information and the ways we can consume it with just AI alone is so vast that if we’re not arming people with the right information in real time, we’re missing the boat.”Natalie Mancuso, SVP, Data Partnerships This means media should be aligned to where a patient or provider is in the decision journey and what they need at that moment. Early on, media may play an educational role by building awareness of a condition, symptom, or treatment category. Later, it may help support more specific questions, treatment consideration, access, affordability, or adherence. The patient-provider conversation remains the key boundary. That exchange should stay private and clinically led. Media can play a valuable role before and after those moments by offering information that helps patients and providers feel more informed. How can brands connect patient and HCP messaging responsibly? It’s critical for agencies and brands to deliver relevant messaging to inform each stakeholder’s needs throughout the treatment journey, especially ahead of key clinical milestones. To execute this, brands must exercise privacy-forward activation, keeping patient and HCP identity, activation, and measurement paths separate, while using a common workflow layer to support the same brand goal. Experian helps pharma marketers do this by acting as an independent, privacy-forward identity, data, and workflow layer. We bring together high-fidelity matching, governed onboarding, and non-clinical consumer context, so patient and HCP engagement can be activated more accurately across channels and connected to reporting. The distinction is not only where each audience is reached. HCPs may be engaged in both professional and personal environments, but their needs are different from patients’. For example, an HCP may receive messaging about co-pay savings for eligible patients, while a patient may receive information about patient support programs. These are different messages for different audiences, but they ladder up to the same goal: informing both parties in a privacy-forward, relevant way. Hear from Natalie Mancuso in our 2026 State of advertising report In our 2026 State of advertising report, Natalie shares why identity serves as the connective infrastructure that links planning, activation, and measurement across connected TV (CTV), programmatic, commerce media, and walled garden environments. Download the report Watch Natalie’s Q&A What does privacy-forward activation look like in pharma? Pharma brands often start with fragmented patient and HCP signals. Privacy-forward activation turns those inputs into usable audiences by first confirming that the data can be used, then translating identity in controlled environments that protect personally identifiable information through tokenization or other methodologies. For DTC, that means building and matching audiences without relying on inferred health conditions from browsing behavior. For HCPs, it means connecting professional identity to verified sources in a way that supports activation and measurement. In a category shaped by HIPAA, state privacy laws, internal review, and consumer sensitivity, building privacy in from sourcing through activation is what makes responsible health media possible. How can CTV play a more useful role in pharma? CTV can play a more useful role in healthcare when it’s connected to a larger, privacy-forward plan and not treated as just an awareness channel. DeepIntent connects CTV and digital exposure data using identity signals, such as National Provider Identifiers (NPIs), hashed email addresses, IP addresses, device IDs, and household signals, where permitted and reviewed. That identity layer helps support sequencing and suppression across streaming, endemic, mobile, and digital settings. In practice, CTV can introduce targeted education or broad brand awareness, and later touchpoints can provide sequential information in the right channels. Instead of repeating the same message, brands can make pivots based on engagement and context. “For us, it starts with identity and not panels. When we’re resolving CTV and digital exposures to the same person, we’re leveraging signals so that every touchpoint across streaming, endemic, and mobile is recognized as the same individual, not model lookalikes.”Natalie Mancuso, SVP, Data Partnerships For pharma, campaign performance should not be measured by reach alone. A stronger approach looks at whether sequenced engagement contributes to meaningful downstream signals, including: Prescription activity Provider engagement Referral patterns Patient compliance Adherence signals, where measurement is permitted Why should messaging and reporting change in pharma? Pharma campaigns are journeys with changing information needs. Reporting should guide the campaign optimization. “If I’m launching into a market with a new class of drug, I’m asking what education needs to be put into the market – from both an HCP and a consumer standpoint – to build awareness?”Natalie Mancuso, SVP, Data Partnerships Clicks and website visits still have a place, but they can’t tell the full pharma story. DeepIntent processes data in real time, giving brands an up-to-date read on how media connects to campaign engagement. Campaign signals can help teams optimize audience logic, creative, channel mix, or sequencing during a live campaign. Heading Test for Media & Text Block Content Test for Media &Text Block Learn more Heading Test for Media & Text Block Content Test for Media &Text Block Learn more Heading Test for Media & Text Block Content Test for Media &Text Block Learn more Explore how privacy-safe pharma activation can make an impact Experian brings marketing data and identity expertise for health marketing and DeepIntent adds pharma-specific activation experience. Together, we help brands connect patient and HCP strategies responsibly, with privacy built in from the start. Watch the full video with our experts to hear Sheila Wirick and Natalie Mancuso discuss patient and HCP messaging, CTV, privacy-safe activation, and outcome measurement for pharma brands. About our experts Natalie Mancuso SVP, Data Partnerships, DeepIntent Natalie Mancuso is SVP, Data Partnerships at DeepIntent and a leader in health-focused AdTech and DSP strategy. With over 20 years of experience growing billion-dollar healthcare brands, she turns complex data into scalable, performance-driven solutions that keep marketers ahead of industry change. Sheila Wirick Director of Health Sales, Experian Sheila Wirick is the Director of Health Sales at Experian with more than 20 years of experience in data and analytics. As Director of Health Sales at Experian Marketing Services, she collaborates with healthcare, pharmaceutical, and nonprofit organizations to apply data and insights that enhance customer retention, brand awareness, and acquisition. She is committed to helping organizations use data to deliver measurable results and meaningful impact. FAQs What makes a pharma audience activation-ready? A pharma audience is activation-ready when patient or HCP inputs can be translated into usable audiences with the right accuracy, controls, interoperability, and destination readiness. For patient engagement, that may include privacy-safe cohort construction, caregiver logic, non-clinical enrichment and appropriate exclusion rules. For HCP engagement, it may include governed identity inputs such as NPI, specialty, practice location, professional address and other verified attributes where appropriate. How can pharma brands sequence messages across channels responsibly? Pharma brands can sequence messages responsibly by giving each channel a clear role and using audience logic to maintain continuity. CTV and out-of-home can support awareness, social can reinforce the message, search can capture active research and point-of-care or rep-triggered channels can support decision moments. The workflow should preserve separation between patient and HCP identity strategies. What should pharma marketers measure beyond clicks and site visits? Pharma marketers should measure whether media connects to outcomes such as audience quality, prescription activity, qualified HCP engagement, verified delivery, referral patterns, therapy starts or adherence signals where permitted. These outcomes often depend on partner-enabled workflows, clean rooms, and aggregated outputs rather than direct end-to-end tracking. How does Experian help pharma brands connect identity, activation and measurement? Experian acts as an independent privacy-first identity, data, and workflow layer for pharma marketers. We help brands bring together identity, high-fidelity matching, governed onboarding, non-clinical consumer context, and partner interoperability so patient and HCP engagement can be activated more accurately across channels and connected more cleanly to partner-enabled measurement. Latest posts
Heading This is my content Heading This is my content Title sdf sdf sdf sdf sdf sdf sdf
Use case #1: Identifying customer spending potential to boost growth for a retail chain Objective Solution Results The solution By syncing its cookies with the Digital Graph, the DSP gained access to related identifiers, including: This expanded identity universe gave the DSP a unified view of individuals and households, making it possible to connect impressions to conversions across devices and channels. With each weekly refresh, attribution models stayed accurate and up to date, turning fragmented signals into proof of performance. Results Within weeks, the DSP saw measurable improvements